>>**Entry Name: Marimastat,** BAN, USAN

Synonym(s): N^4-[2,2-Dimethyl-1-[(methylamino)carbonyl]propyl]-*N*',2-dihydroxy-3-(2-methylpropyl)butanediamide, 9CI. 3-[[2,2-Dimethyl-1-(methylcarbamoyl)propyl] carbamoyl]-2-hydroxy-5-methylhexanohydroxamic acid. BB 2516



CAS Registry Number: 154039-60-8

Molecular Formula: $C_{15}H_{29}N_3O_5$
Molecular Weight: 331.411
Accurate Mass: 331.210722
Percentage Composition: C 54.36%; H 8.82%; N 12.68%; O 24.14%

Use/Importance: Matrix metalloproteinase inhibitor. Antineoplastic agent
Development Status: In clin. trials (1998)
Other Data: Characterised spectroscopically

References:

Pat. Coop. Treaty (WIPO), 1994, 94 02447, *(British Biotech)*
Gore, M. *et al.*, *Lancet*, 1996, **ii**, 263, *(clin trial)*
Pat. Coop. Treaty (WIPO), 1996, *British Biotech*, 96 25 156; *CA*, **125**, 266005, *(pharmacol)*
Pat. Coop. Treaty (WIPO), 1996, *British Biotech*, 96 16 931; *CA*, **125**, 143329, *(analogues, synth)*
Bramhall, S.R.*, Int. J. Pancreatol.*, 1997, **21**, 1, *(pharmacol, clin trial)*
Millar, A.W. *et al.*, *Br. J. Clin. Pharmacol.*, 1998, **45**, 21-26, *(hplc, pharmacokinet, man)*
Nemunaitis, J. *et al.*, *Clin. Cancer Res.*, 1998, **4**, 1101-1109, *(clin trial)*
Wojitowicz-Praga, S. *et al.*, *J. Clin. Oncol.*, 1998, **16**, 2150-2156, *(clin trial, hplc-ms, tox)*
Davenport, R.J. *et al.*, *Tet. Lett.*, 2000, **41**, 7983-7986, *(synth)*

https://www.baizuoyan.com - CopyRight ©baizuoyan